Atopica vet. (15 - 55 kg)
Active substance
ATC code
Species
Dogs (weighing from 15 to 55 kg)
Indications
Treatment of chronic manifestations of atopic dermatitis in dogs.
Dose to be administered and administration route
For oral use.
To ensure a correct dosage, body weight should be determined as accurately as possible.
The mean recommended dose of ciclosporin is 5 mg/kg body weight according to the following scheme.
For a dog weighing 15 to < 29 kg one capsule of the veterinary medicinal product
For a dog weighing 36 to < 55 kg three capsules of the veterinary medicinal product
The veterinary medicinal product will initially be given daily until a satisfactory clinical improvement is seen. This will generally be the case within 4 weeks. If no response is obtained within the first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic dermatitis are satisfactorily controlled, the veterinary medicinal product can then be given every other day as a maintenance dose. The veterinarian should perform a clinical assessment at regular intervals and adjust the frequency of administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every-other-day dosing, the veterinarian can decide to give the veterinary medicinal product every 3 to 4 days.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before reducing the dosing interval.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of clinical signs, treatment should be resumed at daily dosing, and in certain cases repeated treatment courses may be required.
The veterinary medicinal product should be given at least 2 hours before or after feeding. Insert the capsule directly into the dog’s mouth.
Adverse reactions
Dogs:
|
Uncommon (1 to 10 animals / 1,000 animals treated): |
Digestive tract disorders (Vomiting, Mucous stool, Loose stool, Diarrhoea)1. |
|
Rare (1 to 10 animals / 10,000 animals treated): |
Lethargy2, Anorexia2; Hyperactivity2; Gingival hyperplasia2,3; Skin reactions (Verruciform lesions; Hair change)2; Pinnal reddening2, Pinnal oedema2; Muscle weakness2, Cramp2. |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Diabetes mellitus4. |
1generally mild and transient and do not require the cessation
2 generally resolve spontaneously after treatment is stopped
3mild to moderate
4 mainly in West Highland White Terriers
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 00879/5015 |
| EAN | 5037694023348 |
